Crosstalk between SUMOylation and other post-translational modifications in breast cancer

TL;DR

This review explores how SUMOylation interacts with other protein modifications to influence breast cancer development and progression.

Contribution

The paper highlights novel mechanisms of crosstalk between SUMOylation and other post-translational modifications in breast cancer.

Findings

SUMOylation interacts with phosphorylation, ubiquitination, acetylation, and methylation in breast cancer.

Crosstalk between PTMs is protein- and site-specific, affecting cancer progression.

Altered protein conformations and amino acid charges underlie these interactions.

Abstract

Breast cancer represents the most prevalent tumor type and a foremost cause of mortality among women globally. The complex pathophysiological processes of breast cancer tumorigenesis and progression are regulated by protein post-translational modifications (PTMs), which are triggered by different carcinogenic factors and signaling pathways, with small ubiquitin-like modifier (SUMOylation) emerging as a particularly pivotal player in this context. Recent studies have demonstrated that SUMOylation does not act alone, but interacts with other PTMs, such as phosphorylation, ubiquitination, acetylation, and methylation, thereby leading to the regulation of various pathological activities in breast cancer. This review explores novel and existing mechanisms of crosstalk between SUMOylation and other PTMs. Typically, SUMOylation is regulated by phosphorylation to exert feedback control, while also modulates subsequent ubiquitination, acetylation, or methylation. The crosstalk pairs in promoting or inhibiting breast cancer are protein-specific and site-specific. In mechanism, alterations in amino acid side chain charges, protein conformations, or the occupation of specific sites at specific domains or sites underlie the complex crosstalk. In summary, this review centers on elucidating the crosstalk between SUMOylation and other PTMs in breast cancer oncogenesis and progression and discuss the molecular mechanisms contributing to these interactions, offering insights into their potential applications in facilitating novel treatments for breast cancer.

Figures